MX2022010394A - Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. - Google Patents
Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.Info
- Publication number
- MX2022010394A MX2022010394A MX2022010394A MX2022010394A MX2022010394A MX 2022010394 A MX2022010394 A MX 2022010394A MX 2022010394 A MX2022010394 A MX 2022010394A MX 2022010394 A MX2022010394 A MX 2022010394A MX 2022010394 A MX2022010394 A MX 2022010394A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- same
- histone deacetylase
- inhibitor
- derivative compounds
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 1,3,4-oxadiazole derivative compounds Chemical class 0.000 title 1
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 title 1
- 102000011427 Histone Deacetylase 6 Human genes 0.000 abstract 4
- 108010023925 Histone Deacetylase 6 Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a un nuevo compuesto que tiene una actividad inhibidora de histona desacetilasa 6 (HDAC6), a un isómero del mismo o a una sal farmacéuticamente aceptable del mismo, al uso del mismo para preparar un medicamento terapéutico; a una composición farmacéutica que contiene el mismo y a un método de tratamiento que utiliza la composición; y a un método de preparación del mismo. El nuevo compuesto, el isómero del mismo, o la sal farmacéuticamente aceptable del mismo, según la presente invención, tiene la actividad inhibidora de HDAC6, que es eficaz en la prevención o el tratamiento de enfermedades mediadas por HDAC6, incluyendo cáncer, enfermedades inflamatorias, enfermedades autoinmunitarias, enfermedades neurológicas o neurodegenerativas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200023249A KR102537616B1 (ko) | 2020-02-25 | 2020-02-25 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PCT/KR2021/002362 WO2021172886A1 (en) | 2020-02-25 | 2021-02-25 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010394A true MX2022010394A (es) | 2022-09-07 |
Family
ID=77490107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010394A MX2022010394A (es) | 2020-02-25 | 2021-02-25 | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US12466827B2 (es) |
| EP (1) | EP4110780B1 (es) |
| JP (1) | JP7525662B2 (es) |
| KR (1) | KR102537616B1 (es) |
| CN (1) | CN115151542B (es) |
| AU (1) | AU2021225683B2 (es) |
| BR (1) | BR112022016743A2 (es) |
| CA (1) | CA3167361C (es) |
| DK (1) | DK4110780T3 (es) |
| ES (1) | ES2993711T3 (es) |
| FI (1) | FI4110780T3 (es) |
| HR (1) | HRP20241315T1 (es) |
| HU (1) | HUE068550T2 (es) |
| MX (1) | MX2022010394A (es) |
| MY (1) | MY200481A (es) |
| NZ (1) | NZ791043A (es) |
| PH (1) | PH12022552238A1 (es) |
| PT (1) | PT4110780T (es) |
| TW (1) | TWI786553B (es) |
| WO (1) | WO2021172886A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| WO2021021979A2 (en) | 2019-07-30 | 2021-02-04 | Eikonizo Therapapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| KR102537615B1 (ko) | 2020-02-25 | 2023-05-30 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679408B (zh) * | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
| US20090005374A1 (en) * | 2007-06-26 | 2009-01-01 | Melvin Jr Lawrence S | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| TWI482771B (zh) * | 2009-05-04 | 2015-05-01 | Du Pont | 磺醯胺殺線蟲劑 |
| EP2456757B1 (en) | 2009-07-22 | 2019-05-01 | The Board of Trustees of the University of Illionis | Hdac inhibitors and therapeutic methods using the same |
| US20130005721A1 (en) | 2009-09-23 | 2013-01-03 | Panmira Pharmaceuticals, Llc | Indolizine inhibitors of 5-lipoxygenase |
| HUE030679T2 (en) | 2010-01-22 | 2017-05-29 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| JP6047563B2 (ja) | 2011-07-08 | 2016-12-21 | ノバルティス アーゲー | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の治療におけるその使用 |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| US9499479B2 (en) | 2011-10-03 | 2016-11-22 | The Trustees Of Columbia University In The City Of New York | Molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| JP5966014B2 (ja) | 2011-11-28 | 2016-08-10 | ノバルティス アーゲー | 新規トリフルオロメチル−オキサジアゾール誘導体および疾患の処置におけるその使用 |
| EP2822926A4 (en) | 2012-03-07 | 2015-11-04 | H Lee Moffitt Cancer Ct & Res | SELECTIVE HISTON DEACTY LASE-6 HEMMER |
| HK1244318A1 (zh) | 2015-02-02 | 2018-08-03 | 奥特拉公司 | 用於生物标志物检测的不稳定的接头 |
| PT3330259T (pt) | 2015-07-27 | 2020-09-03 | Chong Kun Dang Pharmaceutical Corp | Composto derivado de 1,3,4-oxadiazol amida como inibidor de histona desacetilase 6, e composição farmacêutica que contêm o mesmo |
| MY197262A (en) | 2015-07-27 | 2023-06-08 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2017018805A1 (en) | 2015-07-27 | 2017-02-02 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| TWI694075B (zh) | 2015-08-04 | 2020-05-21 | 韓商鐘根堂股份有限公司 | 作為組蛋白去乙醯酶６抑制劑之１,３,４-㗁二唑衍生物及含彼之醫藥組合物 |
| WO2017030938A1 (en) | 2015-08-14 | 2017-02-23 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| WO2017222950A1 (en) * | 2016-06-23 | 2017-12-28 | Merck Sharp & Dohme Corp. | 3-heterocyclyl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| US11066396B2 (en) | 2016-06-23 | 2021-07-20 | Merck Sharp & Dohme Corp. | 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors |
| CN111406054B (zh) | 2017-12-05 | 2024-01-02 | 奥莱松基因组股份有限公司 | 作为组蛋白脱乙酰基酶6抑制剂的1，2，4-噁二唑衍生物 |
| CR20220325A (es) | 2019-12-20 | 2022-08-19 | Tenaya Therapeutics Inc | Fluoroalquil-oxadiazoles y sus usos |
| KR102537615B1 (ko) | 2020-02-25 | 2023-05-30 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
-
2020
- 2020-02-25 KR KR1020200023249A patent/KR102537616B1/ko active Active
-
2021
- 2021-02-25 MX MX2022010394A patent/MX2022010394A/es unknown
- 2021-02-25 DK DK21760387.7T patent/DK4110780T3/da active
- 2021-02-25 HR HRP20241315TT patent/HRP20241315T1/hr unknown
- 2021-02-25 PH PH1/2022/552238A patent/PH12022552238A1/en unknown
- 2021-02-25 CN CN202180016680.4A patent/CN115151542B/zh active Active
- 2021-02-25 NZ NZ791043A patent/NZ791043A/en unknown
- 2021-02-25 MY MYPI2022004533A patent/MY200481A/en unknown
- 2021-02-25 TW TW110106772A patent/TWI786553B/zh active
- 2021-02-25 WO PCT/KR2021/002362 patent/WO2021172886A1/en not_active Ceased
- 2021-02-25 ES ES21760387T patent/ES2993711T3/es active Active
- 2021-02-25 HU HUE21760387A patent/HUE068550T2/hu unknown
- 2021-02-25 JP JP2022576784A patent/JP7525662B2/ja active Active
- 2021-02-25 BR BR112022016743A patent/BR112022016743A2/pt unknown
- 2021-02-25 FI FIEP21760387.7T patent/FI4110780T3/fi active
- 2021-02-25 US US17/904,806 patent/US12466827B2/en active Active
- 2021-02-25 AU AU2021225683A patent/AU2021225683B2/en active Active
- 2021-02-25 EP EP21760387.7A patent/EP4110780B1/en active Active
- 2021-02-25 CA CA3167361A patent/CA3167361C/en active Active
- 2021-02-25 PT PT217603877T patent/PT4110780T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102537616B1 (ko) | 2023-05-26 |
| BR112022016743A2 (pt) | 2022-10-18 |
| HUE068550T2 (hu) | 2025-01-28 |
| EP4110780B1 (en) | 2024-08-07 |
| US12466827B2 (en) | 2025-11-11 |
| DK4110780T3 (da) | 2024-10-21 |
| AU2021225683B2 (en) | 2023-12-07 |
| FI4110780T3 (fi) | 2024-10-25 |
| JP7525662B2 (ja) | 2024-07-30 |
| TW202146408A (zh) | 2021-12-16 |
| AU2021225683A1 (en) | 2022-09-01 |
| EP4110780A4 (en) | 2023-07-05 |
| CA3167361A1 (en) | 2021-09-02 |
| WO2021172886A1 (en) | 2021-09-02 |
| ES2993711T3 (en) | 2025-01-07 |
| TWI786553B (zh) | 2022-12-11 |
| PH12022552238A1 (en) | 2024-02-12 |
| PT4110780T (pt) | 2024-10-07 |
| CN115151542A (zh) | 2022-10-04 |
| NZ791043A (en) | 2025-09-26 |
| CA3167361C (en) | 2025-05-27 |
| MY200481A (en) | 2023-12-28 |
| HRP20241315T1 (hr) | 2024-12-20 |
| JP2023516824A (ja) | 2023-04-20 |
| EP4110780A1 (en) | 2023-01-04 |
| KR20210108274A (ko) | 2021-09-02 |
| US20230147859A1 (en) | 2023-05-11 |
| CN115151542B (zh) | 2025-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010402A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| MX2018001193A (es) | Compuestos de derivados de 1,3,4-oxadiazolsulfonamida como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos. | |
| MX2022010394A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
| SA522433000B1 (ar) | مركبات فلورو ألكيل-أوكساديازول واستخداماتها | |
| PE20242299A1 (es) | Composiciones agonistas de gip/glp1 | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| CO2023005342A2 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer | |
| MX2019012884A (es) | Terapia de combinacion. | |
| PE20240881A1 (es) | Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t | |
| PH12021552930A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| MX2023000625A (es) | Nuevos compuestos como inhibidor de histona desacetilasa 6, y composicion farmaceutica que los comprende. | |
| UY37837A (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| MX2022010748A (es) | Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1). | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CL2021003312A1 (es) | Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma. | |
| CL2025000529A1 (es) | Compuestos derivados de dioxoisoquinolinona, inhibidores de ezh1 y/o ezh2; uso para tratar cáncer. | |
| AR128257A1 (es) | Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| PH12022552712A1 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| MX2019004842A (es) | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. | |
| MX2024012290A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidor de la histona desacetilasa 6, y usos de los mismos | |
| UY37745A (es) | Compuestos bicíclicos 5,6 fusionados y composiciones para el tratamiento de las enfermedades parasitarias | |
| UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
| PA8579701A1 (es) | Profarmaco inhibidor de beta-lactamasa |